Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch

Executive Summary

Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.

You may also be interested in...



Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods

Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.

Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods

Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.

Biosimilar Legal Landscape: Lessons From 2017

In several firsts last year, US Supreme Court ruled on BPCIA, Amgen won a damages award in infringement litigation, and Amgen and Mylan inked deals clearing way for future launch of Humira and Herceptin biosimilars. Chart includes status of 15 cases and questions teed up for courts to tackle in 2018.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel